Luciole Medical

Executive Summary

Luciole Medical AG is a Swiss medical device company founded in 2019, headquartered in Lausanne, that is transforming cerebral monitoring through advanced hemodynamic sensing. The company has developed an integrated brain monitoring patch, intracranial probe, and analytics platform that provide real-time, non-invasive or minimally invasive assessment of brain health. This technology addresses a critical need in neurocritical care, where early detection of cerebral hypoxia, ischemia, and autoregulation failure can significantly improve patient outcomes. Luciole has already obtained CE-mark and MDR certification, positioning it for commercial deployment in European markets. The company's innovative approach leverages deep understanding of brain hemodynamics, offering a platform that could become the standard of care in ICUs and during neurosurgery. Luciole Medical operates in a growing market driven by increasing incidence of neurological disorders and a shift toward continuous, non-invasive monitoring. Its validated technology and regulatory milestones give it a competitive edge over traditional methods. The company is likely focused on expanding commercial reach, securing distribution partnerships, and pursuing FDA clearance to enter the U.S. market. With a strong IP portfolio and a clear clinical value proposition, Luciole is well-positioned for growth. Key upcoming events include potential FDA 510(k) submission or clearance, strategic partnerships with larger medical device firms, and scaling of manufacturing to meet demand. These catalysts could drive valuation growth and position the company for a successful exit or further fundraising.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) submission or clearance for brain monitoring system60% success
• Q2 2026Strategic partnership or distribution agreement with a global medtech company50% success
• Q3 2026Series B or C funding round to support U.S. expansion and commercialization70% success